chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate increased, SARS-CoV-2 test, SARS-CoV-2 test positive
Clinical narrative: Narrative: COVID infection following COVID vaccine series 05/11/2020 COVID swab, result: not detected 05/12 CXR impression: No Acute cardiopulmonary abnormality 01/07, Pfizer, dose #1 (NON-FACILITY) 01/28, Pfizer, dose #2 (NON-FACILITY) 08/12 pt cc: cough, fatigue, fever, dyspnea, exposure: unknown 08/22 COVID swab, result: detected 08/22 pt admit to medicine cc: shortness of breath dx: COVID-19 Pneumonia LOS: 7 days 08/22 CXR impression: interval development of bilateral airspace opacities. 08/22 FIBRINOGEN result: 480 08/22 DDIMER result: 6.08 08/22 SARS-COV-2 Variant Sequencing result: pending 08/22 FERRITIN result: 369.8 08/23 https://portal.vaers.org/rsa/intranet/images4/2023/3/2601587P_138f238e-4870-401c-ab59-856a11c1a193.jpgFIBRINOGEN result: 391 08/23 ESR result: 33 08/23 DDIMER result: 5.89 08/24 FIBRINOGEN result: 391 08/24 DDIMER result: 3.52 08/27 ESR result: 5 08/28 FIBRINOGEN result: 179 08/28 DDIMER result: 2.20 08/28 ESR result: <1 08/29 FIBRINOGEN result: 156 08/29 DDIMER result: 1.82 08/29 ESR 1
Age: 88.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, COVID-19 pneumonia, Sepsis
Clinical narrative: Narrative: Pneumonia due to coronavirus disease 2019 J12.82(ICD-10-CM) Other specified sepsis A41.89(ICD-10-CM) Acute respiratory failure with hypoxia
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Cardiac failure congestive, Troponin normal, Viral myocarditis, Viral test negative
Clinical narrative: Narrative:  Patient received first dose COVID-19 vaccine (Pfizer) on 8/30/21.About 7-10 days later started to experience new onset CHF concerning for viral myocarditis. His lab markers are negative at the time of this report (RVP, troponin) due to the several day gap between symptoms and evaluation. Pt reports his children and dog had respiratory symptoms before the pt developed symptoms. The ID team felt this was not bacterial or fungal in etiology. ID felt he likely suffered a viral myocarditis as outlined above and may have had underflying CHF (given alcohol abuse and OSA), but the team could not rule out the possible side effect from the COVID-19 vaccine.
Age: 87.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, COVID-19, COVID-19 pneumonia, Chronic obstructive pulmonary disease, Condition aggravated
Clinical narrative: Narrative:  Patient completed Pfizer vaccine series and was later hospitalized with COVID.
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Pleural effusion
Clinical narrative: Narrative:  Patient completed Pfizer vaccine series and was later hospitalized with COVID.
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Cardiomegaly, Chest X-ray abnormal, Chest discomfort
Clinical narrative: Narrative: Admission: 8/30/2021 Discharge 9/10/2021 in stable condition 74yo M w/ hx bradycardia, sick sinus syndrome s/p pacemaker (2016), HTN, asthma, DM (last A1c 5.2, not on meds, obstructive sleep apnea on CPAP, hx DVT not on anticoagulation, presented to Emergency Room with worsening SOB and cough. First symptomatic on 8/22, had progressively worsening SOB w/ productive cough (yellow sputum). Reported increasing dyspnea on exertion, inability to climb small flight of stairs without feeling SOB, subjective fever/chills, coughing/SOB at night making it difficult to sleep. When walking complained of chest heaviness, difficulty catching breath. Received 2 doses Moderna Covid vaccine vaccine in Dec 2020/Jan 2021. Tested positive for COVID 8/27/2021. Tested positive for COVID 8/30/2021. No other complaints. Admitted for COVID pneumonia with sepsis: Tested positive for COVID 8/27 with symptom onset 8/22. Required up to 4L O2 in Emergency Department. Treated with remdesivir, oral dexamethasone and enoxaparin. Discharged 9/10/2021 in stable condition.
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chills, Cough, Dyspnoea, Dyspnoea exertional, Insomnia
Clinical narrative: Narrative: Admission: 8/30/2021 Discharge 9/10/2021 in stable condition 74yo M w/ hx bradycardia, sick sinus syndrome s/p pacemaker (2016), HTN, asthma, DM (last A1c 5.2, not on meds, obstructive sleep apnea on CPAP, hx DVT not on anticoagulation, presented to Emergency Room with worsening SOB and cough. First symptomatic on 8/22, had progressively worsening SOB w/ productive cough (yellow sputum). Reported increasing dyspnea on exertion, inability to climb small flight of stairs without feeling SOB, subjective fever/chills, coughing/SOB at night making it difficult to sleep. When walking complained of chest heaviness, difficulty catching breath. Received 2 doses Moderna Covid vaccine vaccine in Dec 2020/Jan 2021. Tested positive for COVID 8/27/2021. Tested positive for COVID 8/30/2021. No other complaints. Admitted for COVID pneumonia with sepsis: Tested positive for COVID 8/27 with symptom onset 8/22. Required up to 4L O2 in Emergency Department. Treated with remdesivir, oral dexamethasone and enoxaparin. Discharged 9/10/2021 in stable condition.
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Lung opacity, Osteoarthritis, Productive cough, Pulmonary congestion, Pulmonary oedema
Clinical narrative: Narrative: Admission: 8/30/2021 Discharge 9/10/2021 in stable condition 74yo M w/ hx bradycardia, sick sinus syndrome s/p pacemaker (2016), HTN, asthma, DM (last A1c 5.2, not on meds, obstructive sleep apnea on CPAP, hx DVT not on anticoagulation, presented to Emergency Room with worsening SOB and cough. First symptomatic on 8/22, had progressively worsening SOB w/ productive cough (yellow sputum). Reported increasing dyspnea on exertion, inability to climb small flight of stairs without feeling SOB, subjective fever/chills, coughing/SOB at night making it difficult to sleep. When walking complained of chest heaviness, difficulty catching breath. Received 2 doses Moderna Covid vaccine vaccine in Dec 2020/Jan 2021. Tested positive for COVID 8/27/2021. Tested positive for COVID 8/30/2021. No other complaints. Admitted for COVID pneumonia with sepsis: Tested positive for COVID 8/27 with symptom onset 8/22. Required up to 4L O2 in Emergency Department. Treated with remdesivir, oral dexamethasone and enoxaparin. Discharged 9/10/2021 in stable condition.
Age: 75.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive, Sepsis, Sputum discoloured
Clinical narrative: Narrative: Admission: 8/30/2021 Discharge 9/10/2021 in stable condition 74yo M w/ hx bradycardia, sick sinus syndrome s/p pacemaker (2016), HTN, asthma, DM (last A1c 5.2, not on meds, obstructive sleep apnea on CPAP, hx DVT not on anticoagulation, presented to Emergency Room with worsening SOB and cough. First symptomatic on 8/22, had progressively worsening SOB w/ productive cough (yellow sputum). Reported increasing dyspnea on exertion, inability to climb small flight of stairs without feeling SOB, subjective fever/chills, coughing/SOB at night making it difficult to sleep. When walking complained of chest heaviness, difficulty catching breath. Received 2 doses Moderna Covid vaccine vaccine in Dec 2020/Jan 2021. Tested positive for COVID 8/27/2021. Tested positive for COVID 8/30/2021. No other complaints. Admitted for COVID pneumonia with sepsis: Tested positive for COVID 8/27 with symptom onset 8/22. Required up to 4L O2 in Emergency Department. Treated with remdesivir, oral dexamethasone and enoxaparin. Discharged 9/10/2021 in stable condition.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Asthenia, Blood fibrinogen normal, Brain natriuretic peptide normal, COVID-19
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/21/2020, Pfizer, dose #1 01/11/2021, Pfizer, dose #2 08/22 CXR impression: Mild, hazy left basilar pulmonary opacity. Pneumonia could be considered. Cardiomegaly. No evidence of left-sided heart failure. 08/22 pt admit to medicine cc: Generalized weakness, shortness of breath, cough dx: COVID-19 Pneumonia, Acute on Chronic Hypoxic Respiratory Failure LOS: 4 days 08/22 pt cc: exposure: unknown 08/22 COVID swab, result: detected 08/22 SARS-COV-2 Variant Sequencing result: pending 08/22 TROPONIN I result: 0.048 08/22 bnp result: 16.0 08/22 DDIMER result: 0.49 08/23 PROCALCITONIN result: <0.05 08/23 ESR result: 46 08/23 FIBRINOGEN result: 371 08/23 DDIMER result: 0.46 08/23 SARS-CoV-2 AB result: >2500.0 08/24 SARS-COV-2 IGG Eval result: 0.23 08/24 FIBRINOGEN result: 312 08/24 DDIMER result: 0.31 08/24 ESR result: 53 08/25 ESR result: 42 08/25 FIBRINOGEN result: 300 08/25 DDIMER result: <0.22 08/26 ESR result: 33 08/26 FIBRINOGEN result: 245 08/26 DDIMER result: 0.23
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Cardiomegaly, Chest X-ray abnormal, Cough, Dyspnoea
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/21/2020, Pfizer, dose #1 01/11/2021, Pfizer, dose #2 08/22 CXR impression: Mild, hazy left basilar pulmonary opacity. Pneumonia could be considered. Cardiomegaly. No evidence of left-sided heart failure. 08/22 pt admit to medicine cc: Generalized weakness, shortness of breath, cough dx: COVID-19 Pneumonia, Acute on Chronic Hypoxic Respiratory Failure LOS: 4 days 08/22 pt cc: exposure: unknown 08/22 COVID swab, result: detected 08/22 SARS-COV-2 Variant Sequencing result: pending 08/22 TROPONIN I result: 0.048 08/22 bnp result: 16.0 08/22 DDIMER result: 0.49 08/23 PROCALCITONIN result: <0.05 08/23 ESR result: 46 08/23 FIBRINOGEN result: 371 08/23 DDIMER result: 0.46 08/23 SARS-CoV-2 AB result: >2500.0 08/24 SARS-COV-2 IGG Eval result: 0.23 08/24 FIBRINOGEN result: 312 08/24 DDIMER result: 0.31 08/24 ESR result: 53 08/25 ESR result: 42 08/25 FIBRINOGEN result: 300 08/25 DDIMER result: <0.22 08/26 ESR result: 33 08/26 FIBRINOGEN result: 245 08/26 DDIMER result: 0.23
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: Fibrin D dimer, Lung opacity, Procalcitonin, Red blood cell sedimentation rate increased, Respiratory failure
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/21/2020, Pfizer, dose #1 01/11/2021, Pfizer, dose #2 08/22 CXR impression: Mild, hazy left basilar pulmonary opacity. Pneumonia could be considered. Cardiomegaly. No evidence of left-sided heart failure. 08/22 pt admit to medicine cc: Generalized weakness, shortness of breath, cough dx: COVID-19 Pneumonia, Acute on Chronic Hypoxic Respiratory Failure LOS: 4 days 08/22 pt cc: exposure: unknown 08/22 COVID swab, result: detected 08/22 SARS-COV-2 Variant Sequencing result: pending 08/22 TROPONIN I result: 0.048 08/22 bnp result: 16.0 08/22 DDIMER result: 0.49 08/23 PROCALCITONIN result: <0.05 08/23 ESR result: 46 08/23 FIBRINOGEN result: 371 08/23 DDIMER result: 0.46 08/23 SARS-CoV-2 AB result: >2500.0 08/24 SARS-COV-2 IGG Eval result: 0.23 08/24 FIBRINOGEN result: 312 08/24 DDIMER result: 0.31 08/24 ESR result: 53 08/25 ESR result: 42 08/25 FIBRINOGEN result: 300 08/25 DDIMER result: <0.22 08/26 ESR result: 33 08/26 FIBRINOGEN result: 245 08/26 DDIMER result: 0.23
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 antibody test, SARS-CoV-2 test, SARS-CoV-2 test positive, Troponin I increased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/21/2020, Pfizer, dose #1 01/11/2021, Pfizer, dose #2 08/22 CXR impression: Mild, hazy left basilar pulmonary opacity. Pneumonia could be considered. Cardiomegaly. No evidence of left-sided heart failure. 08/22 pt admit to medicine cc: Generalized weakness, shortness of breath, cough dx: COVID-19 Pneumonia, Acute on Chronic Hypoxic Respiratory Failure LOS: 4 days 08/22 pt cc: exposure: unknown 08/22 COVID swab, result: detected 08/22 SARS-COV-2 Variant Sequencing result: pending 08/22 TROPONIN I result: 0.048 08/22 bnp result: 16.0 08/22 DDIMER result: 0.49 08/23 PROCALCITONIN result: <0.05 08/23 ESR result: 46 08/23 FIBRINOGEN result: 371 08/23 DDIMER result: 0.46 08/23 SARS-CoV-2 AB result: >2500.0 08/24 SARS-COV-2 IGG Eval result: 0.23 08/24 FIBRINOGEN result: 312 08/24 DDIMER result: 0.31 08/24 ESR result: 53 08/25 ESR result: 42 08/25 FIBRINOGEN result: 300 08/25 DDIMER result: <0.22 08/26 ESR result: 33 08/26 FIBRINOGEN result: 245 08/26 DDIMER result: 0.23
Age: 95.0
Sex: M
Vaccine: COVID19
Symptoms: Death
Clinical narrative: Narrative:  94yo patient who does not receive medical care from agency, died on 9/24/2021. No information rearding pt's death available. Pt had hx of dementia, chronic afib and history of cva. Pt did receive covid vaccines on 4/7/21 & 5/15/21. Likely this death is not related to covid vaccines given patient's advanced age, comorbidities, and long length of time between date of vaccines and date of death.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Acute left ventricular failure, Blood pressure decreased, Cardiac failure acute, Death, Deep vein thrombosis
Clinical narrative: Narrative:  74yo male patient died during inpatient hospice admission. Date and Time of Death: Oct 1,2021@19:05 Death was caused by: acute heart failure unresponsive to Additional comments: Dx with DVT 2 weeks ago. Then this admission, dx with endocarditis and septic shock plus multiple PE and new pancreatic tail mass with liver and local nodal metastasis. developed acute systolic HF - EF was 60% 9/27 and 20% 9/30. Additionally metabolic acidosis and was in need of HD but thought to be a poor candidate. Then patient's bp continued to decline despite increase in norepi and later addition of milrinone When more alert/clear earlier today, chose to be dnr with no lsts. Then worsened during day. HCS opted for hospice and was supported by patients living relatives - his two brothers and his step mother. when family was around bedside, pressors were stopped and comfort meds were given. Patient died peacefully. Pt had received covid vaccines on 2/3/21 & 3/5/21. Likely this death is not related to covid vaccines given patient's age, comorbidities, and long length of time between date of vaccines and date of death.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Ejection fraction decreased, Endocarditis, General physical health deterioration, Metabolic acidosis, Metastases to liver
Clinical narrative: Narrative:  74yo male patient died during inpatient hospice admission. Date and Time of Death: Oct 1,2021@19:05 Death was caused by: acute heart failure unresponsive to Additional comments: Dx with DVT 2 weeks ago. Then this admission, dx with endocarditis and septic shock plus multiple PE and new pancreatic tail mass with liver and local nodal metastasis. developed acute systolic HF - EF was 60% 9/27 and 20% 9/30. Additionally metabolic acidosis and was in need of HD but thought to be a poor candidate. Then patient's bp continued to decline despite increase in norepi and later addition of milrinone When more alert/clear earlier today, chose to be dnr with no lsts. Then worsened during day. HCS opted for hospice and was supported by patients living relatives - his two brothers and his step mother. when family was around bedside, pressors were stopped and comfort meds were given. Patient died peacefully. Pt had received covid vaccines on 2/3/21 & 3/5/21. Likely this death is not related to covid vaccines given patient's age, comorbidities, and long length of time between date of vaccines and date of death.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Metastases to lymph nodes, Pancreatic mass, Septic shock
Clinical narrative: Narrative:  74yo male patient died during inpatient hospice admission. Date and Time of Death: Oct 1,2021@19:05 Death was caused by: acute heart failure unresponsive to Additional comments: Dx with DVT 2 weeks ago. Then this admission, dx with endocarditis and septic shock plus multiple PE and new pancreatic tail mass with liver and local nodal metastasis. developed acute systolic HF - EF was 60% 9/27 and 20% 9/30. Additionally metabolic acidosis and was in need of HD but thought to be a poor candidate. Then patient's bp continued to decline despite increase in norepi and later addition of milrinone When more alert/clear earlier today, chose to be dnr with no lsts. Then worsened during day. HCS opted for hospice and was supported by patients living relatives - his two brothers and his step mother. when family was around bedside, pressors were stopped and comfort meds were given. Patient died peacefully. Pt had received covid vaccines on 2/3/21 & 3/5/21. Likely this death is not related to covid vaccines given patient's age, comorbidities, and long length of time between date of vaccines and date of death.
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Cerebrovascular accident, Death, Loss of personal independence in daily activities, Seizure
Clinical narrative: Narrative: 85yo male patient died at home in home hospice care on 9/27/2021. Pt had started home hospice care on 09/23/2021. Pt had suffered a CVA verses seizure disorder seizure which caused a change in status causing the need for full care. Pt had receivec covid vaccines on 5/11/21 & 4/13/21. Likely this death is not related to covid vaccines given patient's age, comorbidities, and long length of time between date of vaccines and date of death.
Age: 75.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death
Clinical narrative: Narrative: Patient contracted COVID-19 despite vaccination and passed away 8/23/21
Age: 90.0
Sex: M
Vaccine: COVID19
Symptoms: Cardiomyopathy, Chronic kidney disease, Fluid retention
Clinical narrative: Narrative: Patient with CKD, cardiomyopathy with fluid retention
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute kidney injury, Blood alkaline phosphatase normal, Blood bicarbonate decreased, Blood creatinine increased, C-reactive protein increased
Clinical narrative: Narrative:  Admission Date: Oct 6,2021 Discharge Date: Oct 7,2021 Condition of patient at discharge: Stable Primary Diagnosis during Admission/Treatment: COVID-19 Secondary Diagnosis during Admission/Treatment: AKI 71yoM with PMH HTN, HLD, DMII, CAD s/p CABG, GERD, CKD, PAD s/p femoral stent, who presented with 1 week of fever, chills, SOB, and malaise to the Emergency Department. Patient reported one week of shortness of breath that started on Monday 10/4/2021. Then he began to experience global myalgias and fatigue. In the ED, patient was initially hypoxic to 86% on Room Air, improved to 96% on 3L by Nasal Cannula. Otherwise febrile to 100.6F, tachycardic to 115, tachypneic to 24 resp rate. Labs are significant for elevated inflammatory markers ESR:130 CRP:9.14, d-dimer 0.52, creatinine 1.99 (BL 1.4), bicarb 17, ALP 55. CXR demonstrates mild-moderate right lung pneumonia. COVID positive despite being fully vaccinated with Pfizer COVID vaccine on 1/26/2021 and 2/18/2021. He was admitted for further mgmt of COVID-19 infection. The patient was started on dexamethasone and remdesivir as described in this report. The following day, he had no complaints of shortness of breath and was satting in the mid to high 90's on room air. He underwent a walk test with nusrsing staff on room air that afternoon. His lowest SpO2 recorded was 89%. Therefore, remdesivir and dexamethasone were discontinued and the patient was discharged later in the day.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Chest X-ray abnormal, Chills, Dyspnoea, Fatigue
Clinical narrative: Narrative:  Admission Date: Oct 6,2021 Discharge Date: Oct 7,2021 Condition of patient at discharge: Stable Primary Diagnosis during Admission/Treatment: COVID-19 Secondary Diagnosis during Admission/Treatment: AKI 71yoM with PMH HTN, HLD, DMII, CAD s/p CABG, GERD, CKD, PAD s/p femoral stent, who presented with 1 week of fever, chills, SOB, and malaise to the Emergency Department. Patient reported one week of shortness of breath that started on Monday 10/4/2021. Then he began to experience global myalgias and fatigue. In the ED, patient was initially hypoxic to 86% on Room Air, improved to 96% on 3L by Nasal Cannula. Otherwise febrile to 100.6F, tachycardic to 115, tachypneic to 24 resp rate. Labs are significant for elevated inflammatory markers ESR:130 CRP:9.14, d-dimer 0.52, creatinine 1.99 (BL 1.4), bicarb 17, ALP 55. CXR demonstrates mild-moderate right lung pneumonia. COVID positive despite being fully vaccinated with Pfizer COVID vaccine on 1/26/2021 and 2/18/2021. He was admitted for further mgmt of COVID-19 infection. The patient was started on dexamethasone and remdesivir as described in this report. The following day, he had no complaints of shortness of breath and was satting in the mid to high 90's on room air. He underwent a walk test with nusrsing staff on room air that afternoon. His lowest SpO2 recorded was 89%. Therefore, remdesivir and dexamethasone were discontinued and the patient was discharged later in the day.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fibrin D dimer, Hypoxia, Inflammatory marker increased, Lung infiltration, Malaise
Clinical narrative: Narrative:  Admission Date: Oct 6,2021 Discharge Date: Oct 7,2021 Condition of patient at discharge: Stable Primary Diagnosis during Admission/Treatment: COVID-19 Secondary Diagnosis during Admission/Treatment: AKI 71yoM with PMH HTN, HLD, DMII, CAD s/p CABG, GERD, CKD, PAD s/p femoral stent, who presented with 1 week of fever, chills, SOB, and malaise to the Emergency Department. Patient reported one week of shortness of breath that started on Monday 10/4/2021. Then he began to experience global myalgias and fatigue. In the ED, patient was initially hypoxic to 86% on Room Air, improved to 96% on 3L by Nasal Cannula. Otherwise febrile to 100.6F, tachycardic to 115, tachypneic to 24 resp rate. Labs are significant for elevated inflammatory markers ESR:130 CRP:9.14, d-dimer 0.52, creatinine 1.99 (BL 1.4), bicarb 17, ALP 55. CXR demonstrates mild-moderate right lung pneumonia. COVID positive despite being fully vaccinated with Pfizer COVID vaccine on 1/26/2021 and 2/18/2021. He was admitted for further mgmt of COVID-19 infection. The patient was started on dexamethasone and remdesivir as described in this report. The following day, he had no complaints of shortness of breath and was satting in the mid to high 90's on room air. He underwent a walk test with nusrsing staff on room air that afternoon. His lowest SpO2 recorded was 89%. Therefore, remdesivir and dexamethasone were discontinued and the patient was discharged later in the day.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Myalgia, Pneumonia, Pyrexia, Red blood cell sedimentation rate increased, SARS-CoV-2 test positive
Clinical narrative: Narrative:  Admission Date: Oct 6,2021 Discharge Date: Oct 7,2021 Condition of patient at discharge: Stable Primary Diagnosis during Admission/Treatment: COVID-19 Secondary Diagnosis during Admission/Treatment: AKI 71yoM with PMH HTN, HLD, DMII, CAD s/p CABG, GERD, CKD, PAD s/p femoral stent, who presented with 1 week of fever, chills, SOB, and malaise to the Emergency Department. Patient reported one week of shortness of breath that started on Monday 10/4/2021. Then he began to experience global myalgias and fatigue. In the ED, patient was initially hypoxic to 86% on Room Air, improved to 96% on 3L by Nasal Cannula. Otherwise febrile to 100.6F, tachycardic to 115, tachypneic to 24 resp rate. Labs are significant for elevated inflammatory markers ESR:130 CRP:9.14, d-dimer 0.52, creatinine 1.99 (BL 1.4), bicarb 17, ALP 55. CXR demonstrates mild-moderate right lung pneumonia. COVID positive despite being fully vaccinated with Pfizer COVID vaccine on 1/26/2021 and 2/18/2021. He was admitted for further mgmt of COVID-19 infection. The patient was started on dexamethasone and remdesivir as described in this report. The following day, he had no complaints of shortness of breath and was satting in the mid to high 90's on room air. He underwent a walk test with nusrsing staff on room air that afternoon. His lowest SpO2 recorded was 89%. Therefore, remdesivir and dexamethasone were discontinued and the patient was discharged later in the day.
Age: 71.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Tachycardia, Tachypnoea, Walking distance test
Clinical narrative: Narrative:  Admission Date: Oct 6,2021 Discharge Date: Oct 7,2021 Condition of patient at discharge: Stable Primary Diagnosis during Admission/Treatment: COVID-19 Secondary Diagnosis during Admission/Treatment: AKI 71yoM with PMH HTN, HLD, DMII, CAD s/p CABG, GERD, CKD, PAD s/p femoral stent, who presented with 1 week of fever, chills, SOB, and malaise to the Emergency Department. Patient reported one week of shortness of breath that started on Monday 10/4/2021. Then he began to experience global myalgias and fatigue. In the ED, patient was initially hypoxic to 86% on Room Air, improved to 96% on 3L by Nasal Cannula. Otherwise febrile to 100.6F, tachycardic to 115, tachypneic to 24 resp rate. Labs are significant for elevated inflammatory markers ESR:130 CRP:9.14, d-dimer 0.52, creatinine 1.99 (BL 1.4), bicarb 17, ALP 55. CXR demonstrates mild-moderate right lung pneumonia. COVID positive despite being fully vaccinated with Pfizer COVID vaccine on 1/26/2021 and 2/18/2021. He was admitted for further mgmt of COVID-19 infection. The patient was started on dexamethasone and remdesivir as described in this report. The following day, he had no complaints of shortness of breath and was satting in the mid to high 90's on room air. He underwent a walk test with nusrsing staff on room air that afternoon. His lowest SpO2 recorded was 89%. Therefore, remdesivir and dexamethasone were discontinued and the patient was discharged later in the day.
Age: 87.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Chest X-ray abnormal, Chills, Chronic obstructive pulmonary disease, Cough
Clinical narrative: Narrative: Admission Date Oct 8,2021 Discharge Date: Oct 9,2021 Condition of patient at discharge: Stable Disposition of Patient at Discharge: Home Primary Diagnosis during Admission/Treatment: COVID-19 86yo patient with history of Afib (not on anticoagulation), alcohol and smoking history, and dementia who presented to the Emergency Room with nausea and vomiting. Patient noted acute onset nausea and vomiting on day of admission. He did not note any abdominal pain. He also noted fatigue, SOB, and cough with new production as well. Endorsed subjective fevers and chills. In the Emergency Department, the patient was afebrile with HR 110, RR in 30s, and BP 189/116. Reported hypoxia requiring 2L O2. CXR with pulmonary infiltrate on L midlung and COPD. Labs notable for WBC 11.62 and COVID positive despite being fully vaccinated w/ Pfizer vaccine for Covid-19 on 2/2/2021 and 2/23/2021. UA with 250 LE and WBC 51-100. After he was admitted to the hospital, the patient was stable on Room Air, received INV-CASIRIVIMAB/IMDEVIMAB INJ product, and was stable for discharge the following day.
Age: 87.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Fatigue, Hypoxia, Lung infiltration, Nausea
Clinical narrative: Narrative: Admission Date Oct 8,2021 Discharge Date: Oct 9,2021 Condition of patient at discharge: Stable Disposition of Patient at Discharge: Home Primary Diagnosis during Admission/Treatment: COVID-19 86yo patient with history of Afib (not on anticoagulation), alcohol and smoking history, and dementia who presented to the Emergency Room with nausea and vomiting. Patient noted acute onset nausea and vomiting on day of admission. He did not note any abdominal pain. He also noted fatigue, SOB, and cough with new production as well. Endorsed subjective fevers and chills. In the Emergency Department, the patient was afebrile with HR 110, RR in 30s, and BP 189/116. Reported hypoxia requiring 2L O2. CXR with pulmonary infiltrate on L midlung and COPD. Labs notable for WBC 11.62 and COVID positive despite being fully vaccinated w/ Pfizer vaccine for Covid-19 on 2/2/2021 and 2/23/2021. UA with 250 LE and WBC 51-100. After he was admitted to the hospital, the patient was stable on Room Air, received INV-CASIRIVIMAB/IMDEVIMAB INJ product, and was stable for discharge the following day.
Age: 87.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Productive cough, Pyrexia, SARS-CoV-2 test positive, Vomiting, White blood cell count increased
Clinical narrative: Narrative: Admission Date Oct 8,2021 Discharge Date: Oct 9,2021 Condition of patient at discharge: Stable Disposition of Patient at Discharge: Home Primary Diagnosis during Admission/Treatment: COVID-19 86yo patient with history of Afib (not on anticoagulation), alcohol and smoking history, and dementia who presented to the Emergency Room with nausea and vomiting. Patient noted acute onset nausea and vomiting on day of admission. He did not note any abdominal pain. He also noted fatigue, SOB, and cough with new production as well. Endorsed subjective fevers and chills. In the Emergency Department, the patient was afebrile with HR 110, RR in 30s, and BP 189/116. Reported hypoxia requiring 2L O2. CXR with pulmonary infiltrate on L midlung and COPD. Labs notable for WBC 11.62 and COVID positive despite being fully vaccinated w/ Pfizer vaccine for Covid-19 on 2/2/2021 and 2/23/2021. UA with 250 LE and WBC 51-100. After he was admitted to the hospital, the patient was stable on Room Air, received INV-CASIRIVIMAB/IMDEVIMAB INJ product, and was stable for discharge the following day.
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Blood fibrinogen normal, COVID-19, Fibrin D dimer, Red blood cell sedimentation rate normal
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/29/2020, Pfizer, dose #1 01/22/2021, Pfizer, dose #2 09/23/2021, Pfizer, dose #3 08/27 COVID swab, result: detected 08/27 SARS-COV-2 Variant Sequencing result: pending 08/29 pt cc: No symptoms exposure: unknown 08/31 TROPONIN I 0.156 08/31 pt admit to Medicine cc: Generalized weakness dx: COVID19 Mil LOS: 4 08/31 ESR 10 09/01 FIBRINOGEN result: 258 09/01 DDIMER result: 0.41 09/01 ESR 10 09/02 FIBRINOGEN result: 261 09/02 DDIMER result: 0.35 09/02 ESR 9 09/03 FIBRINOGEN result: 235 09/03DDIMER result: <0.22 09/03 ESR 13
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, SARS-CoV-2 test positive, Troponin I increased
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/29/2020, Pfizer, dose #1 01/22/2021, Pfizer, dose #2 09/23/2021, Pfizer, dose #3 08/27 COVID swab, result: detected 08/27 SARS-COV-2 Variant Sequencing result: pending 08/29 pt cc: No symptoms exposure: unknown 08/31 TROPONIN I 0.156 08/31 pt admit to Medicine cc: Generalized weakness dx: COVID19 Mil LOS: 4 08/31 ESR 10 09/01 FIBRINOGEN result: 258 09/01 DDIMER result: 0.41 09/01 ESR 10 09/02 FIBRINOGEN result: 261 09/02 DDIMER result: 0.35 09/02 ESR 9 09/03 FIBRINOGEN result: 235 09/03DDIMER result: <0.22 09/03 ESR 13
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Blood fibrinogen increased, COVID-19, COVID-19 pneumonia, Chest X-ray abnormal, Cough
Clinical narrative: Narrative: COVID infection following COVID vaccine series 5/01 Janssen, dose #1 (non agency) 08/22 COVID swab, result: detected 08/22 CXR impression: Streaky right basilar opacity may be due to atelectasis versus early infiltrate. Please note a viral pneumonia may not have significant radiographic findings. Clinical correlation is recommended. 08/22 pt admit to medicine cc: Cough, lethargic dx: COVID-19 Pneumonia LOS: 2 days 08/22 pt cc: cough, dyspnea exposure: unknown 08/22 SARS-COV-2 Variant Sequencing result: pending 08/23 troponin i result: <0.016 08/23 DDIMER result: 0.39 08/23 procalcitonin result: 0.07 08/24 FIBRINOGEN result: 440 08/24 DDIMER result: 0.30 08/24 ESR result 26 08/24 SARS-COV-2 Variant Sequencing result: pending 08/24 SARS-COV-2 IGG result; 0.01 08/25 FIBRINOGEN result: 469 08/25 DDIMER result: 0.37 08/25 ESR 11
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea, Fibrin D dimer, Lethargy, Lung opacity, Procalcitonin
Clinical narrative: Narrative: COVID infection following COVID vaccine series 5/01 Janssen, dose #1 (non agency) 08/22 COVID swab, result: detected 08/22 CXR impression: Streaky right basilar opacity may be due to atelectasis versus early infiltrate. Please note a viral pneumonia may not have significant radiographic findings. Clinical correlation is recommended. 08/22 pt admit to medicine cc: Cough, lethargic dx: COVID-19 Pneumonia LOS: 2 days 08/22 pt cc: cough, dyspnea exposure: unknown 08/22 SARS-COV-2 Variant Sequencing result: pending 08/23 troponin i result: <0.016 08/23 DDIMER result: 0.39 08/23 procalcitonin result: 0.07 08/24 FIBRINOGEN result: 440 08/24 DDIMER result: 0.30 08/24 ESR result 26 08/24 SARS-COV-2 Variant Sequencing result: pending 08/24 SARS-COV-2 IGG result; 0.01 08/25 FIBRINOGEN result: 469 08/25 DDIMER result: 0.37 08/25 ESR 11
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate increased, SARS-CoV-2 antibody test, SARS-CoV-2 test, SARS-CoV-2 test positive, Troponin I normal
Clinical narrative: Narrative: COVID infection following COVID vaccine series 5/01 Janssen, dose #1 (non agency) 08/22 COVID swab, result: detected 08/22 CXR impression: Streaky right basilar opacity may be due to atelectasis versus early infiltrate. Please note a viral pneumonia may not have significant radiographic findings. Clinical correlation is recommended. 08/22 pt admit to medicine cc: Cough, lethargic dx: COVID-19 Pneumonia LOS: 2 days 08/22 pt cc: cough, dyspnea exposure: unknown 08/22 SARS-COV-2 Variant Sequencing result: pending 08/23 troponin i result: <0.016 08/23 DDIMER result: 0.39 08/23 procalcitonin result: 0.07 08/24 FIBRINOGEN result: 440 08/24 DDIMER result: 0.30 08/24 ESR result 26 08/24 SARS-COV-2 Variant Sequencing result: pending 08/24 SARS-COV-2 IGG result; 0.01 08/25 FIBRINOGEN result: 469 08/25 DDIMER result: 0.37 08/25 ESR 11
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Blood fibrinogen normal, Brain natriuretic peptide increased, COVID-19
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/29/2020 , Pfizer, dose #1 01/19/2021 Pfizer, dose #2 08/23 COVID swab, result: detected 08/21 pt cc: cough, dyspnea, fatigue exposure: unknown 08/23 pt admit to medicine cc: General fatigue and shortness of breath dx: Acute hypoxic respiratory failure LOS: 5 days 08/23 CTA PE impression: Negative study for acute pulmonary embolism. Multifocal pneumonia, with the largest opacity in the RIGHT lower lobe. Recommend PA and lateral chest radiographs in 6-8 weeks after appropriate treatment to document resolution. 08/23 CXR impression: No acute pulmonary finding. 08/25 FIBRINOGEN result: 491 08/25DDIMER result: 0.99 08/25 ESR result: 41 08/26 FIBRINOGEN result: 378 08/26 DDIMER result: 0.6 08/26 ESR result: 30 08/27 FIBRINOGEN result: 326 08/27 DDIMER result: 1.56 08/27 ESR result: 21 09/05 pt traveled and was readmitted non-agency hospital LOS: unknown 09/09 COVID-19 ANTIGEN(BINAX) result: not detected 09/09 ESR result: 7 09/09 CTA PE impression: No pulmonary embolus. Since prior CT dated 8/23/2021, some worsening of multifocal airspace and groundglass opacities, consistent with known viral pneumonia, again most pronounced in the right lower lobe. 09/09 BNP result: 106.3 09/09 procalcitonin result: <0.05 09/09 pt admit to cc: General fatigue and shortness of breath dx: COVID Pneumonia LOS: 1 day 09/10 FIBRINOGEN result: 250 09/10 DDIMER result: 1.41 09/10 ESR result: 10
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Chest X-ray normal, Computerised tomogram thorax abnormal, Cough, Dyspnoea
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/29/2020 , Pfizer, dose #1 01/19/2021 Pfizer, dose #2 08/23 COVID swab, result: detected 08/21 pt cc: cough, dyspnea, fatigue exposure: unknown 08/23 pt admit to medicine cc: General fatigue and shortness of breath dx: Acute hypoxic respiratory failure LOS: 5 days 08/23 CTA PE impression: Negative study for acute pulmonary embolism. Multifocal pneumonia, with the largest opacity in the RIGHT lower lobe. Recommend PA and lateral chest radiographs in 6-8 weeks after appropriate treatment to document resolution. 08/23 CXR impression: No acute pulmonary finding. 08/25 FIBRINOGEN result: 491 08/25DDIMER result: 0.99 08/25 ESR result: 41 08/26 FIBRINOGEN result: 378 08/26 DDIMER result: 0.6 08/26 ESR result: 30 08/27 FIBRINOGEN result: 326 08/27 DDIMER result: 1.56 08/27 ESR result: 21 09/05 pt traveled and was readmitted non-agency hospital LOS: unknown 09/09 COVID-19 ANTIGEN(BINAX) result: not detected 09/09 ESR result: 7 09/09 CTA PE impression: No pulmonary embolus. Since prior CT dated 8/23/2021, some worsening of multifocal airspace and groundglass opacities, consistent with known viral pneumonia, again most pronounced in the right lower lobe. 09/09 BNP result: 106.3 09/09 procalcitonin result: <0.05 09/09 pt admit to cc: General fatigue and shortness of breath dx: COVID Pneumonia LOS: 1 day 09/10 FIBRINOGEN result: 250 09/10 DDIMER result: 1.41 09/10 ESR result: 10
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Fibrin D dimer, Lung opacity, Pneumonia viral, Procalcitonin
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/29/2020 , Pfizer, dose #1 01/19/2021 Pfizer, dose #2 08/23 COVID swab, result: detected 08/21 pt cc: cough, dyspnea, fatigue exposure: unknown 08/23 pt admit to medicine cc: General fatigue and shortness of breath dx: Acute hypoxic respiratory failure LOS: 5 days 08/23 CTA PE impression: Negative study for acute pulmonary embolism. Multifocal pneumonia, with the largest opacity in the RIGHT lower lobe. Recommend PA and lateral chest radiographs in 6-8 weeks after appropriate treatment to document resolution. 08/23 CXR impression: No acute pulmonary finding. 08/25 FIBRINOGEN result: 491 08/25DDIMER result: 0.99 08/25 ESR result: 41 08/26 FIBRINOGEN result: 378 08/26 DDIMER result: 0.6 08/26 ESR result: 30 08/27 FIBRINOGEN result: 326 08/27 DDIMER result: 1.56 08/27 ESR result: 21 09/05 pt traveled and was readmitted non-agency hospital LOS: unknown 09/09 COVID-19 ANTIGEN(BINAX) result: not detected 09/09 ESR result: 7 09/09 CTA PE impression: No pulmonary embolus. Since prior CT dated 8/23/2021, some worsening of multifocal airspace and groundglass opacities, consistent with known viral pneumonia, again most pronounced in the right lower lobe. 09/09 BNP result: 106.3 09/09 procalcitonin result: <0.05 09/09 pt admit to cc: General fatigue and shortness of breath dx: COVID Pneumonia LOS: 1 day 09/10 FIBRINOGEN result: 250 09/10 DDIMER result: 1.41 09/10 ESR result: 10
Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate increased, SARS-CoV-2 test positive
Clinical narrative: Narrative:  COVID infection following COVID vaccine series 12/29/2020 , Pfizer, dose #1 01/19/2021 Pfizer, dose #2 08/23 COVID swab, result: detected 08/21 pt cc: cough, dyspnea, fatigue exposure: unknown 08/23 pt admit to medicine cc: General fatigue and shortness of breath dx: Acute hypoxic respiratory failure LOS: 5 days 08/23 CTA PE impression: Negative study for acute pulmonary embolism. Multifocal pneumonia, with the largest opacity in the RIGHT lower lobe. Recommend PA and lateral chest radiographs in 6-8 weeks after appropriate treatment to document resolution. 08/23 CXR impression: No acute pulmonary finding. 08/25 FIBRINOGEN result: 491 08/25DDIMER result: 0.99 08/25 ESR result: 41 08/26 FIBRINOGEN result: 378 08/26 DDIMER result: 0.6 08/26 ESR result: 30 08/27 FIBRINOGEN result: 326 08/27 DDIMER result: 1.56 08/27 ESR result: 21 09/05 pt traveled and was readmitted non-agency hospital LOS: unknown 09/09 COVID-19 ANTIGEN(BINAX) result: not detected 09/09 ESR result: 7 09/09 CTA PE impression: No pulmonary embolus. Since prior CT dated 8/23/2021, some worsening of multifocal airspace and groundglass opacities, consistent with known viral pneumonia, again most pronounced in the right lower lobe. 09/09 BNP result: 106.3 09/09 procalcitonin result: <0.05 09/09 pt admit to cc: General fatigue and shortness of breath dx: COVID Pneumonia LOS: 1 day 09/10 FIBRINOGEN result: 250 09/10 DDIMER result: 1.41 09/10 ESR result: 10
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Angiogram pulmonary abnormal, Atypical pneumonia, Blood bicarbonate increased, Blood fibrinogen increased
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/05, Pfizer, dose #1 01/27, Pfizer, dose #2 08/24 pt cc: No symptoms exposure: unknown 08/24 CTA PE impression: Bilateral pneumonia. Viral pneumonia is within the differential. No pulmonary embolus. 08/24 CXR impression: Bilateral lung opacities most consistent with multifocal pneumonia including atypical/viral pneumonia. Follow-up to resolution after appropriate treatment recommended. 08/24 COVID swab, result: detected 08/2 pt admit to Medicine cc: shortness of breath & fever dx: Bilateral Pneumonia / Covid-19 (+) Acute Hypoxemic respiratory failure LOS: 5 days 08/24 PROCALCITONIN result: 0.27 08/24 DDIMER result: 11.61 08/24 ferritin result: 1295.6 08/24 LACTC ACID result: 0.83 08/24 ABG result: i-pH 7.51, i-PCO2 39.0, i-PO2 50, i-HCO3 30.9 08/24 COVID-19 ANTIGEN (BINAX) result: not detected 08/24 IRON SATURATION 21.07 08/24 FERRITIN result: 1299.7 08/24 TRANSFERRIN result: 98 08/24 IRON result: 29 08/24 TSH result: 0.489 08/24 ESR result: 30 08/25 Fibrinogen result: 749 08/25 DDIMER result: 7.05 08/26 ESR result 65 08/26 Fibrinogen result: 459 08/26 DDIMER result: 4.99 08/26 INR result: 1.35 08/26 PT result: 15.1 08/27 ESR result: 37 08/27 Fibrinogen result: 353 08/27 DDIMER result: 4.72 08/28 Fibrinogen result: 391 08/28 DDIMER result: 5.42 08/28 ESR result: 43 08/29 Fibrinogen result: 336 08/29 DDIMER result: 2.44 08/29 ESR result: 18 08/30 ESR 30 08/30 Fibrinogen result: 353 08/30 DDIMER result: 2.02 09/18 CXR result: Improved aeration of the lungs compared to the recent prior studies, but with significant persistent airspace and interstitial opacities suggestive of area of scarring and fibrosis. Persistent or recurrent pneumonia cannot be excluded. Continued attention on follow-up examination is recommended. 09/20 FERRITIN result: 205.4
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Blood gases abnormal, Blood iron, Blood lactic acid, Blood pH increased, Blood thyroid stimulating hormone decreased
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/05, Pfizer, dose #1 01/27, Pfizer, dose #2 08/24 pt cc: No symptoms exposure: unknown 08/24 CTA PE impression: Bilateral pneumonia. Viral pneumonia is within the differential. No pulmonary embolus. 08/24 CXR impression: Bilateral lung opacities most consistent with multifocal pneumonia including atypical/viral pneumonia. Follow-up to resolution after appropriate treatment recommended. 08/24 COVID swab, result: detected 08/2 pt admit to Medicine cc: shortness of breath & fever dx: Bilateral Pneumonia / Covid-19 (+) Acute Hypoxemic respiratory failure LOS: 5 days 08/24 PROCALCITONIN result: 0.27 08/24 DDIMER result: 11.61 08/24 ferritin result: 1295.6 08/24 LACTC ACID result: 0.83 08/24 ABG result: i-pH 7.51, i-PCO2 39.0, i-PO2 50, i-HCO3 30.9 08/24 COVID-19 ANTIGEN (BINAX) result: not detected 08/24 IRON SATURATION 21.07 08/24 FERRITIN result: 1299.7 08/24 TRANSFERRIN result: 98 08/24 IRON result: 29 08/24 TSH result: 0.489 08/24 ESR result: 30 08/25 Fibrinogen result: 749 08/25 DDIMER result: 7.05 08/26 ESR result 65 08/26 Fibrinogen result: 459 08/26 DDIMER result: 4.99 08/26 INR result: 1.35 08/26 PT result: 15.1 08/27 ESR result: 37 08/27 Fibrinogen result: 353 08/27 DDIMER result: 4.72 08/28 Fibrinogen result: 391 08/28 DDIMER result: 5.42 08/28 ESR result: 43 08/29 Fibrinogen result: 336 08/29 DDIMER result: 2.44 08/29 ESR result: 18 08/30 ESR 30 08/30 Fibrinogen result: 353 08/30 DDIMER result: 2.02 09/18 CXR result: Improved aeration of the lungs compared to the recent prior studies, but with significant persistent airspace and interstitial opacities suggestive of area of scarring and fibrosis. Persistent or recurrent pneumonia cannot be excluded. Continued attention on follow-up examination is recommended. 09/20 FERRITIN result: 205.4
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chest X-ray abnormal, Dyspnoea, Fibrin D dimer, International normalised ratio increased
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/05, Pfizer, dose #1 01/27, Pfizer, dose #2 08/24 pt cc: No symptoms exposure: unknown 08/24 CTA PE impression: Bilateral pneumonia. Viral pneumonia is within the differential. No pulmonary embolus. 08/24 CXR impression: Bilateral lung opacities most consistent with multifocal pneumonia including atypical/viral pneumonia. Follow-up to resolution after appropriate treatment recommended. 08/24 COVID swab, result: detected 08/2 pt admit to Medicine cc: shortness of breath & fever dx: Bilateral Pneumonia / Covid-19 (+) Acute Hypoxemic respiratory failure LOS: 5 days 08/24 PROCALCITONIN result: 0.27 08/24 DDIMER result: 11.61 08/24 ferritin result: 1295.6 08/24 LACTC ACID result: 0.83 08/24 ABG result: i-pH 7.51, i-PCO2 39.0, i-PO2 50, i-HCO3 30.9 08/24 COVID-19 ANTIGEN (BINAX) result: not detected 08/24 IRON SATURATION 21.07 08/24 FERRITIN result: 1299.7 08/24 TRANSFERRIN result: 98 08/24 IRON result: 29 08/24 TSH result: 0.489 08/24 ESR result: 30 08/25 Fibrinogen result: 749 08/25 DDIMER result: 7.05 08/26 ESR result 65 08/26 Fibrinogen result: 459 08/26 DDIMER result: 4.99 08/26 INR result: 1.35 08/26 PT result: 15.1 08/27 ESR result: 37 08/27 Fibrinogen result: 353 08/27 DDIMER result: 4.72 08/28 Fibrinogen result: 391 08/28 DDIMER result: 5.42 08/28 ESR result: 43 08/29 Fibrinogen result: 336 08/29 DDIMER result: 2.44 08/29 ESR result: 18 08/30 ESR 30 08/30 Fibrinogen result: 353 08/30 DDIMER result: 2.02 09/18 CXR result: Improved aeration of the lungs compared to the recent prior studies, but with significant persistent airspace and interstitial opacities suggestive of area of scarring and fibrosis. Persistent or recurrent pneumonia cannot be excluded. Continued attention on follow-up examination is recommended. 09/20 FERRITIN result: 205.4
Age: 72.0
Sex: M
Vaccine: COVID19
Symptoms: Interstitial lung disease, Lung opacity, PCO2 normal, PO2 decreased, Pneumonia
Clinical narrative: Narrative: COVID infection following COVID vaccine series 01/05, Pfizer, dose #1 01/27, Pfizer, dose #2 08/24 pt cc: No symptoms exposure: unknown 08/24 CTA PE impression: Bilateral pneumonia. Viral pneumonia is within the differential. No pulmonary embolus. 08/24 CXR impression: Bilateral lung opacities most consistent with multifocal pneumonia including atypical/viral pneumonia. Follow-up to resolution after appropriate treatment recommended. 08/24 COVID swab, result: detected 08/2 pt admit to Medicine cc: shortness of breath & fever dx: Bilateral Pneumonia / Covid-19 (+) Acute Hypoxemic respiratory failure LOS: 5 days 08/24 PROCALCITONIN result: 0.27 08/24 DDIMER result: 11.61 08/24 ferritin result: 1295.6 08/24 LACTC ACID result: 0.83 08/24 ABG result: i-pH 7.51, i-PCO2 39.0, i-PO2 50, i-HCO3 30.9 08/24 COVID-19 ANTIGEN (BINAX) result: not detected 08/24 IRON SATURATION 21.07 08/24 FERRITIN result: 1299.7 08/24 TRANSFERRIN result: 98 08/24 IRON result: 29 08/24 TSH result: 0.489 08/24 ESR result: 30 08/25 Fibrinogen result: 749 08/25 DDIMER result: 7.05 08/26 ESR result 65 08/26 Fibrinogen result: 459 08/26 DDIMER result: 4.99 08/26 INR result: 1.35 08/26 PT result: 15.1 08/27 ESR result: 37 08/27 Fibrinogen result: 353 08/27 DDIMER result: 4.72 08/28 Fibrinogen result: 391 08/28 DDIMER result: 5.42 08/28 ESR result: 43 08/29 Fibrinogen result: 336 08/29 DDIMER result: 2.44 08/29 ESR result: 18 08/30 ESR 30 08/30 Fibrinogen result: 353 08/30 DDIMER result: 2.02 09/18 CXR result: Improved aeration of the lungs compared to the recent prior studies, but with significant persistent airspace and interstitial opacities suggestive of area of scarring and fibrosis. Persistent or recurrent pneumonia cannot be excluded. Continued attention on follow-up examination is recommended. 09/20 FERRITIN result: 205.4